Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

BBP vs PSCH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PSCH Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)

PSCH Overall Winner 6-Pillar Tally: BBP 0 – 0 PSCH (6 Tie) Matrix Metrics: BBP 1 – 2 PSCH

As of Nov 16, 2026, Invesco S&P SmallCap Health Care ETF (PSCH) is the stronger overall head-to-head candidate over Virtus LifeSci Biotech Products ETF (BBP) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). BBP carries a Unified Composite Score of 53.0/100 (HOLD) at $99.30 (N/M Forward P/E, N/A operating margin), whereas PSCH carries 50.1/100 (HOLD) at $56.30 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While BBP currently prints a higher short-term Unified Composite Score (53.0/100 HOLD vs. PSCH 50.1/100 HOLD), PSCH captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
  • Technical & Structure Timing Caution: BBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7); meanwhile PSCH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 55.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BBP vs PSCH
BBP NYSE Arca
Virtus LifeSci Biotech Products ETF
Institutional Equity
$99.30
-2.67% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.94β · 30% Vol
Unified Composite Score
53.0 / 100 HOLD
Tech 37.0 Fund 48.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.9%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $103.53 · SMA50: $103.61
PSCH NASDAQ Head-to-Head Winner
Invesco S&P SmallCap Health Care ETF
Investment Advice
$56.30
-0.98% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.79β · 28% Vol
Unified Composite Score
50.1 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 55
RSI-14: 55.4 · SMA20: $55.73 · SMA50: $53.87

6-Pillar Scorecard Institutional Category Breakdown (BBP 0 – 0 PSCH)

Columns: Metric · BBP · PSCH
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 26.5% (4th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Investment Advice Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BBP (1) vs PSCH (2)
Institutional Metric BBP PSCH Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
70% ($74–$110) 90% ($39–$58) Stronger Trend PSCH
Beta / 30D Volatility
Risk Regime
0.94β · 30% Vol 0.79β · 28% Vol Lower Realized Risk PSCH
Unified Institutional Score
Composite Signal
53.0 / 100 (HOLD) 50.1 / 100 (HOLD) Higher Composite BBP
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PSCH +9.46 pp
BBP: -0.9% · PSCH: +8.56%
3M Horizon PSCH +5.91 pp
BBP: -4.04% · PSCH: +1.87%
6M Horizon PSCH +8.83 pp
BBP: +17.72% · PSCH: +26.55%
1Y Horizon PSCH +2.97 pp
BBP: +30.13% · PSCH: +33.1%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BBP vs PSCH. Trailing 12-month operating profitability (BBP N/A vs PSCH N/A) and valuation multiples (BBP N/M vs PSCH N/M Forward P/E) are benchmarked directly in Pillar 4 below.

BBP ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
PSCH ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BBP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 26.5%
IV Percentile 4th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BBP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PSCH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PSCH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BBP Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PSCH Moat Profile Cyclical / Execution-Driven Positioning
Investment Advice Operator
Competes within the Investment Advice value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ BBP vs PSCH Key Questions & Quantitative Answers

As of Nov 16, 2026, Invesco S&P SmallCap Health Care ETF (PSCH) is the stronger overall head-to-head candidate over Virtus LifeSci Biotech Products ETF (BBP) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). BBP carries a Unified Composite Score of 53.0/100 (HOLD) at $99.30 (N/M Forward P/E, N/A operating margin), whereas PSCH carries 50.1/100 (HOLD) at $56.30 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While BBP currently prints a higher short-term Unified Composite Score (53.0/100 HOLD vs. PSCH 50.1/100 HOLD), PSCH captures the overall institutional head-to-head verdict (2–1 matrix metrics and 0–0 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: BBP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7); meanwhile PSCH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 55.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BBP and PSCH split Growth & Scale metrics: BBP posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with PSCH at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, BBP generates N/A in USD-normalized revenue versus N/A for PSCH. In operating R&D and SG&A reinvestment, BBP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PSCH.

BBP and PSCH trade at balanced relative valuation multiples. BBP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PSCH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BBP (N/A ROE) versus PSCH (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, BBP carries 26.5% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.94β · 30% Vol realized risk). By comparison, PSCH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.79β · 28% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.